Global Chemotherapy-induced Nausea and Vomiting Drugs Industry

Global Chemotherapy-induced Nausea and Vomiting Drugs Industry

  • April 2021 •
  • 134 pages •
  • Report ID: 6040479 •
  • Format: PDF
Abstract:
- Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach $3.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurokinin NK1 Receptor Antagonist segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $667.6 Million, While China is Forecast to Grow at 4.8% CAGR
- The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$667.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$565.6 Million by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
- Dopamine Antagonist Segment to Record 4.8% CAGR
- In the global Dopamine Antagonist segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$294.1 Million in the year 2020 will reach a projected size of US$409.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368.2 Million by the year 2027.

- Select Competitors (Total 41 Featured) -
  • Acacia Pharma Group Plc
  • Aphios Corporation
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Especificos Stendhal S.A. DE C.V.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lee’s Pharmaceutical Holdings Ltd.
  • Merck & Co., Inc.
  • Midatech Pharma PLC
  • Mundipharma Pte., Ltd.
  • Mylan N.V.
  • Ono Pharmaceutical Co., Ltd.
  • Opko Health, Inc.
  • Orchid Chemicals & Pharmaceuticals Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Purdue Pharma LP
  • Sandoz International GmbH
  • SciClone Pharmaceuticals, Inc.
  • Shin Nippon Biomedical Laboratories Ltd. (SNBL)
  • Solasia Pharma K.K.
  • Specialised Therapeutics Asia Pte Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.